Cell And Gene Therapy For Multiple Myeloma Market Positioned for Accelerated Development Through 2032, DelveInsight Finds | J&J, Bristol Myers Squibb, Regeneron, AbbVie, Roche, Janssen Pharma

The Key Cell And Gene Therapy For Multiple Myeloma Companies in the market include - Johnson & Johnson Innovative Medicine, Bristol Myers Squibb, Regeneron, AbbVie and Roche, Janssen Pharmaceutical, Regeneron Pharmaceuticals, Cartesian Therapeutics, Alliance Foundation Trials, LLC., US Oncology Research, GlaxoSmithKline, Targovax ASA, Janssen Research & Development, AstraZeneca, Celgene, Bristol-Myers Squibb, Pfizer, Ascentage Pharma Group Inc., TeneoOne Inc., Novartis, and others.

The Cell And Gene Therapy For Multiple Myeloma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cell And Gene Therapy For Multiple Myeloma pipeline products will significantly revolutionize the Cell And Gene Therapy For Multiple Myeloma market dynamics.

DelveInsight's "Cell And Gene Therapy For Multiple Myeloma Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Cell And Gene Therapy For Multiple Myeloma, historical and forecasted epidemiology as well as the Cell And Gene Therapy For Multiple Myeloma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Cell And Gene Therapy For Multiple Myeloma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Cell And Gene Therapy For Multiple Myeloma Market Forecast [https://www.delveinsight.com/sample-request/cell-and-gene-therapy-for-multiple-myeloma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Cell And Gene Therapy For Multiple Myeloma Market Report:

*
The Cell And Gene Therapy For Multiple Myeloma market size is anticipated to grow with a significant CAGR during the study period (2019-2032).

*
In August 2025, Kelonia Therapeutics, Inc., a biotech firm pioneering in vivo gene delivery, announced that the first patient has been treated in the inMMyCAR Phase 1 trial. The study is testing KLN-1010, an innovative in vivo gene therapy that produces anti-BCMA CAR-T cells, in patients with relapsed or refractory multiple myeloma.

*
In August 2025, The first patient was treated in a Phase 1 clinical trial investigating a gene therapy for individuals with relapsed or treatment-resistant multiple myeloma. Named inMMyCAR (NCT07075185), the study is assessing the safety, pharmacokinetics, and preliminary efficacy of Kelonia Therapeutics' KLN-1010 at multiple sites in Australia, enrolling up to 40 adults. KLN-1010 is designed to produce cancer-fighting CAR-T cells directly within the patient's body following a single administration, removing the need for cell collection, preconditioning chemotherapy, or complex cell manufacturing required by conventional CAR-T therapies. "KLN-1010 represents new hope for multiple myeloma patients unable to access current CAR-T options," stated Kevin Friedman, PhD, CEO and founder of Kelonia. "This first-in-human dosing is a key milestone toward delivering CAR-T therapy without chemotherapy or customized manufacturing, potentially available at nearly any hospital worldwide.

*
In September 2024, Bristol Myers Squibb (BMS) and 2seventy bio have decided to halt enrollment in the Phase III KarMMa-9 clinical trial of Abecma (idecabtagene vicleucel) for newly diagnosed multiple myeloma (NDMM) patients. The study was designed to assess Abecma combined with lenalidomide maintenance compared to lenalidomide maintenance alone following an autologous stem cell transplant in NDMM patients with a suboptimal response.

*
In July 2024, Pfizer halted the Phase III CIFFREO trial assessing the investigational gene therapy fordadistrogene movaparvovec. Previously, the therapy failed to meet the primary objective of improving motor function in boys aged 4 to 7 years compared to a placebo.

*
In July 2024, Miltenyi Biotec signed a Letter of Intent with the Translational Health Science and Technology Institute (THSTI). This collaboration seeks to advance the development of innovative cell and gene therapies to meet the increasing demand for groundbreaking cancer treatments.

*
In May 2024, Taysha Gene Therapies was granted a Regenerative Medicine Advanced Therapy (RMAT) designation by the US Food and Drug Administration (FDA) for its gene therapy candidate, TSHA-102, aimed at treating Rett syndrome.

*
In April 2024, Charles River Laboratories International, Inc. has entered into a plasmid DNA contract development and manufacturing (CDMO) partnership with Axovia Therapeutics Ltd. Under this collaboration, Charles River will produce High Quality (HQ) gene of interest plasmid to aid in the development of Axovia's gene therapies for ciliopathies, including Bardet-Biedl Syndrome (BBS), a rare condition with limited treatment options and no known cure.

*
In April 2024, Ginkgo Bioworks has successfully concluded its gene therapy collaboration with Biogen, which began in May 2021. The partnership focused on improving the industry standards for producing recombinant adeno-associated virus (AAV)-based vectors. The collaboration successfully enhanced AAV production titers in Biogen's gene therapy manufacturing processes, achieving its intended goals.

*
In March 2024, Johnson & Johnson announced that the US Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) has recommended CARVYKTI for treating adult patients with Relapsed/Refractory Cell And Gene Therapy For Multiple Myeloma (RRMM) who have undergone at least one prior therapy, including a proteasome inhibitor and an IMiD, and are refractory to lenalidomide.

*
Key Cell And Gene Therapy For Multiple Myeloma Companies: Johnson & Johnson Innovative Medicine, Bristol Myers Squibb, Regeneron, AbbVie and Roche, Janssen Pharmaceutical, Regeneron Pharmaceuticals, Cartesian Therapeutics, Alliance Foundation Trials, LLC., US Oncology Research, Cartesian Therapeutics, GlaxoSmithKline, Targovax ASA, Janssen Research & Development, AstraZeneca, Celgene, Bristol-Myers Squibb, Pfizer, Ascentage Pharma Group Inc., TeneoOne Inc., Novartis, and others

*
Key Cell And Gene Therapy For Multiple Myeloma Therapies: CARVYKTI (ciltacabtagene autoleucel), Mezigdomide (CC-92480), Linvoseltamab (REGN5458), Venetoclax, ABBV 383, Talquetamab, Linvoseltamab, Descartes 08, Lenalidomide, Selinexor, Descartes-25, Pomalidomide, TG01, Cyclophosphamide, AZD0305, bb2121, EOS884448, Elranatamab, APG-2575, TNB-383B, PHE885, and others

*
The Cell And Gene Therapy For Multiple Myeloma epidemiology based on gender analyzed that males are affected more in case of Cell And Gene Therapy For Multiple Myeloma as compared to females.

*
The Cell And Gene Therapy For Multiple Myeloma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cell And Gene Therapy For Multiple Myeloma pipeline products will significantly revolutionize the Cell And Gene Therapy For Multiple Myeloma market dynamics.

Cell And Gene Therapy For Multiple Myeloma Overview

Cell and gene therapy for multiple myeloma is an advanced treatment approach that modifies a patient's own cells or genetic material to target and destroy cancerous plasma cells. The most common approach is CAR-T (Chimeric Antigen Receptor T-cell) therapy, where T-cells are extracted, genetically engineered to recognize specific antigens on myeloma cells (such as BCMA), and reinfused into the patient to attack the cancer. Other strategies include gene editing and gene-modified stem cell therapies, aimed at enhancing immune response or correcting genetic defects driving the disease. These therapies offer personalized, targeted treatment with potential for long-term remission, especially in relapsed or refractory cases.

Approved CAR-T therapies, such as Abecma (idecabtagene vicleucel) and Carvykti (ciltacabtagene autoleucel), have shown remarkable efficacy in relapsed/refractory MM cases. Other investigational gene-modified therapies, including T-cell receptor (TCR) therapies and CRISPR-based gene edits, are under development.

Get a Free sample for the Cell And Gene Therapy For Multiple Myeloma Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/cell-and-gene-therapy-for-multiple-myeloma-market [https://www.delveinsight.com/report-store/cell-and-gene-therapy-for-multiple-myeloma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Cell And Gene Therapy For Multiple Myeloma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Cell And Gene Therapy For Multiple Myeloma Epidemiology Segmentation:

The Cell And Gene Therapy For Multiple Myeloma market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:

*
Total Prevalence of Cell And Gene Therapy For Multiple Myeloma

*
Prevalent Cases of Cell And Gene Therapy For Multiple Myeloma by severity

*
Gender-specific Prevalence of Cell And Gene Therapy For Multiple Myeloma

*
Diagnosed Cases of Episodic and Chronic Cell And Gene Therapy For Multiple Myeloma

Download the report to understand which factors are driving Cell And Gene Therapy For Multiple Myeloma epidemiology trends @ Cell And Gene Therapy For Multiple Myeloma Epidemiology Forecast [https://www.delveinsight.com/sample-request/cell-and-gene-therapy-for-multiple-myeloma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Cell And Gene Therapy For Multiple Myeloma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cell And Gene Therapy For Multiple Myeloma market or expected to get launched during the study period. The analysis covers Cell And Gene Therapy For Multiple Myeloma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Cell And Gene Therapy For Multiple Myeloma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Cell And Gene Therapy For Multiple Myeloma Therapies and Key Companies

*
CARVYKTI (ciltacabtagene autoleucel): Johnson & Johnson Innovative Medicine

*
Mezigdomide (CC-92480): Bristol Myers Squibb

*
Linvoseltamab (REGN5458): Regeneron

*
Venetoclax: AbbVie and Roche

*
ABBV 383: AbbVie

*
Talquetamab: Janssen Pharmaceutical

*
Linvoseltamab: Regeneron Pharmaceuticals

*
Descartes 08: Cartesian Therapeutics

*
Lenalidomide: Alliance Foundation Trials, LLC.

*
Selinexor: US Oncology Research

*
Descartes-25: Cartesian Therapeutics

*
Pomalidomide: GlaxoSmithKline

*
TG01: Targovax ASA

*
Cyclophosphamide: Janssen Research & Development

*
AZD0305: AstraZeneca

*
bb2121: Celgene

*
EOS884448: Bristol-Myers Squibb

*
Elranatamab: Pfizer

*
APG-2575: Ascentage Pharma Group Inc.

*
TNB-383B: TeneoOne Inc.

*
PHE885: Novartis

Discover more about therapies set to grab major Cell And Gene Therapy For Multiple Myeloma market share @ Cell And Gene Therapy For Multiple Myeloma Treatment Landscape [https://www.delveinsight.com/sample-request/cell-and-gene-therapy-for-multiple-myeloma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Cell And Gene Therapy For Multiple Myeloma Market Strengths

*
Emerging therapies such as CAR-T cell and monoclonal antibodies showing promising results in treating multiple myeloma patients and expected to drive the growth of market. It also amends the treatment landscape in cancer due to its high specificity and minimal side effect profile.

Cell And Gene Therapy For Multiple Myeloma Market Opportunities

*
BCMA-targeting therapies are expected to result in noteworthy revenues due to premium pricing and clinical benefit in heavily pretreated patients.

Scope of the Cell And Gene Therapy For Multiple Myeloma Market Report

*
Study Period: 2019-2032

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Cell And Gene Therapy For Multiple Myeloma Companies: Johnson & Johnson Innovative Medicine, Bristol Myers Squibb, Regeneron, AbbVie and Roche, Janssen Pharmaceutical, Regeneron Pharmaceuticals, Cartesian Therapeutics, Alliance Foundation Trials, LLC., US Oncology Research, Cartesian Therapeutics, GlaxoSmithKline, Targovax ASA, Janssen Research & Development, AstraZeneca, Celgene, Bristol-Myers Squibb, Pfizer, Ascentage Pharma Group Inc., TeneoOne Inc., Novartis, and others

*
Key Cell And Gene Therapy For Multiple Myeloma Therapies: CARVYKTI (ciltacabtagene autoleucel), Mezigdomide (CC-92480), Linvoseltamab (REGN5458), Venetoclax, ABBV 383, Talquetamab, Linvoseltamab, Descartes 08, Lenalidomide, Selinexor, Descartes-25, Pomalidomide, TG01, Cyclophosphamide, AZD0305, bb2121, EOS884448, Elranatamab, APG-2575, TNB-383B, PHE885, and others

*
Cell And Gene Therapy For Multiple Myeloma Therapeutic Assessment: Cell And Gene Therapy For Multiple Myeloma current marketed and Cell And Gene Therapy For Multiple Myeloma emerging therapies

*
Cell And Gene Therapy For Multiple Myeloma Market Dynamics: Cell And Gene Therapy For Multiple Myeloma market drivers and Cell And Gene Therapy For Multiple Myeloma market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Cell And Gene Therapy For Multiple Myeloma Unmet Needs, KOL's views, Analyst's views, Cell And Gene Therapy For Multiple Myeloma Market Access and Reimbursement

To know more about Cell And Gene Therapy For Multiple Myeloma companies working in the treatment market, visit @ Cell And Gene Therapy For Multiple Myeloma Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/cell-and-gene-therapy-for-multiple-myeloma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Cell And Gene Therapy For Multiple Myeloma Market Report Introduction

2. Executive Summary for Cell And Gene Therapy For Multiple Myeloma

3. SWOT analysis of Cell And Gene Therapy For Multiple Myeloma

4. Cell And Gene Therapy For Multiple Myeloma Patient Share (%) Overview at a Glance

5. Cell And Gene Therapy For Multiple Myeloma Market Overview at a Glance

6. Cell And Gene Therapy For Multiple Myeloma Disease Background and Overview

7. Cell And Gene Therapy For Multiple Myeloma Epidemiology and Patient Population

8. Country-Specific Patient Population of Cell And Gene Therapy For Multiple Myeloma

9. Cell And Gene Therapy For Multiple Myeloma Current Treatment and Medical Practices

10. Cell And Gene Therapy For Multiple Myeloma Unmet Needs

11. Cell And Gene Therapy For Multiple Myeloma Emerging Therapies

12. Cell And Gene Therapy For Multiple Myeloma Market Outlook

13. Country-Wise Cell And Gene Therapy For Multiple Myeloma Market Analysis (2019-2032)

14. Cell And Gene Therapy For Multiple Myeloma Market Access and Reimbursement of Therapies

15. Cell And Gene Therapy For Multiple Myeloma Market Drivers

16. Cell And Gene Therapy For Multiple Myeloma Market Barriers

17. Cell And Gene Therapy For Multiple Myeloma Appendix

18. Cell And Gene Therapy For Multiple Myeloma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=cell-and-gene-therapy-for-multiple-myeloma-market-positioned-for-accelerated-development-through-2032-delveinsight-finds-jj-bristol-myers-squibb-regeneron-abbvie-roche-janssen-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.